Home/ Stocks/ GYRE

Gyre Therapeutics, Inc. Common Stock

GYRE XNAS

$8.03 +0.25 (+3.21%) ▲ 15-min delayed

Open

$7.88

High

$8.03

Low

$7.73

Volume

34.2K

Market Cap

$754.61M

About Gyre Therapeutics, Inc. Common Stock

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 618 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$116.59M	$9.88M	$0.06
FY 2025	$116.59M	$9.88M	$0.06
Q3 2025	$30.56M	$8.26M	$0.04
Q2 2025	$26.77M	$1.58M	$0.00

Related Market News

No specific coverage for GYRE yet. Check out our latest market news or earnings calendar.

Get GYRE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Gyre Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.